Riley Myers, PhD

Riley Myers is Director of CMC Policy and Advocacy at GlaxoSmithKline. Prior to joining GSK, he was Director of Technical Operations at the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). Dr Myers spent 11 years at the U.S. Food and Drug Administration, serving in multiple scientific and leadership roles—including the founding Chief of the Advanced Manufacturing Research Facility within CDER’s Office of Pharmaceutical Quality, a member of the Emerging Technology Team, and a founding member of the Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) working group, where he contributed to the development of approaches for regulating future advanced manufacturing technologies. He also served as a Lead Biologist in the Office of Biotechnology Products (now OPQAIII), leading teams responsible for quality assessments. Earlier in his career, Dr. Myers studied mechanisms to program anti-pathogenic immune responses at Boston Children’s Hospital, and he earned his Ph.D. in Immunology from the University of Alabama at Birmingham.